SINO BIOPHARMACEUTICAL LTD financial statements, including revenue, expenses, profit, and loss
The total revenue of SMZ1 for the last semiannual is 1.37 B EUR, and it's 32.27% lower compared to the previous semiannual. The net income of H2 23 is 134.48 M EUR.